Joshua Pinto - 14 Sep 2023 Form 3 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Chief Financial Officer
Signature
/s/ Joshua Pinto
Issuer symbol
NMRA
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
3
Filing time
14 Sep 2023, 18:52:10 UTC
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NMRA Common Stock 238,965 14 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 223,034 $2.52 Direct F1, F2
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 270,828 $2.52 Direct F1, F3
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 223,034 $2.52 Direct F1, F4
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 720,084 $4.63 Direct F1, F5
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 127,448 $6.36 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a 1-for-7.8463 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on September 8, 2023.
F2 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
F3 The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date.
F4 The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date.
F5 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F6 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Exhibit 24 - Power of Attorney